Abstract
In the last few decades, obesity has captured the attention of the medical community, as well as the general public. Obesity has been shown to be a direct cause or a contributor to the development of various chronic diseases. In contrast, higher weight has been linked to better outcomes in patients with chronic obstructive pulmonary disease (COPD). It also has been recognized that “not all weight has been created equal” and its not the absolute weight in kilograms or the body-mass index (BMI), but rather the fat-free mass index (FFMI) that is a better measure of the nutritional status and the overall prognosis in COPD patients. While the impact of the weight and the nutritional status on the lung cancer outcomes has been similar to that of COPD, the relationship between the obesity and asthma has been more complex and multi-faceted. The article will offer a concise, rather than a comprehensive review of such relationships between the nutritional status and the natural history of three chronic lung diseases. The effects of nutritional supplements, alternative medications, and other interventions will be discussed in the context of the individual diseases (COPD, asthma and lung cancer).
Keywords: Obesity, COPD, asthma, lung cancer, body mass index, fat free mass index
Current Respiratory Medicine Reviews
Title: Obesity in the Patient with Lung Disease
Volume: 4 Issue: 2
Author(s): Zaza I. Cohen
Affiliation:
Keywords: Obesity, COPD, asthma, lung cancer, body mass index, fat free mass index
Abstract: In the last few decades, obesity has captured the attention of the medical community, as well as the general public. Obesity has been shown to be a direct cause or a contributor to the development of various chronic diseases. In contrast, higher weight has been linked to better outcomes in patients with chronic obstructive pulmonary disease (COPD). It also has been recognized that “not all weight has been created equal” and its not the absolute weight in kilograms or the body-mass index (BMI), but rather the fat-free mass index (FFMI) that is a better measure of the nutritional status and the overall prognosis in COPD patients. While the impact of the weight and the nutritional status on the lung cancer outcomes has been similar to that of COPD, the relationship between the obesity and asthma has been more complex and multi-faceted. The article will offer a concise, rather than a comprehensive review of such relationships between the nutritional status and the natural history of three chronic lung diseases. The effects of nutritional supplements, alternative medications, and other interventions will be discussed in the context of the individual diseases (COPD, asthma and lung cancer).
Export Options
About this article
Cite this article as:
Cohen I. Zaza, Obesity in the Patient with Lung Disease, Current Respiratory Medicine Reviews 2008; 4 (2) . https://dx.doi.org/10.2174/157339808784222803
DOI https://dx.doi.org/10.2174/157339808784222803 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
HDAC Inhibitor Sodium Butyrate Augments the MEF2C Enhancement of Nampt Expression under Hypoxia
Current Pharmaceutical Design MEK Inhibitors: A Therapeutic Approach to Targeting the Ras-MAP Kinase Pathway in Tumors
Current Pharmaceutical Design Heterologous Production of Death Ligands’ and Death Receptors’ Extracellular Domains: Structural Features and Efficient Systems
Protein & Peptide Letters Deciphering the Role of Forkhead Transcription Factors in Cancer Therapy
Current Drug Targets Meet Our Editorial Board Member
The Natural Products Journal Resveratrol Inhibits the Epithelial-Mesenchymal Transition of Pancreatic Cancer Cells Via Suppression of the PI-3K/Akt/NF-κB Pathway
Current Medicinal Chemistry TFF (Trefoil Factor Family) Peptides and their Potential Roles for Differentiation Processes During Airway Remodeling
Current Medicinal Chemistry Tubulins as Therapeutic Targets in Cancer: from Bench to Bedside
Current Pharmaceutical Design Use of Analogs of Peptide Hormones Conjugated to Cytotoxic Radicals for Chemotherapy Targeted to Receptors on Tumors
Current Drug Delivery Natural Compounds Containing a Condensed Cyclopropane Ring. Natural and Synthetic Aspects
Current Organic Chemistry Identification of Novel Anti-inflammatory Agents from Ayurvedic Medicine for Prevention of Chronic Diseases: “Reverse Pharmacology” and “Bedside to Bench” Approach
Current Drug Targets Synthesis and Anticancer Activity of 2,4,5-triaryl Imidazole Derivatives
Letters in Drug Design & Discovery Resistance to Antiangiogenic: Focus on Mechanisms
Current Angiogenesis (Discontinued) Role of Erlotinib in Influencing the Quality of Life of Cancer Patients
Clinical Cancer Drugs Transplacental Antioxidants Inhibit Lung Tumors in Mice Exposed to Cigarette Smoke After Birth: A Novel Preventative Strategy?
Current Cancer Drug Targets Melanoma Immunotherapy: Past, Present, and Future
Current Pharmaceutical Design NK-1 Receptor Antagonists: A New Paradigm in Pharmacological Therapy
Current Medicinal Chemistry Histone Modifications as Molecular Targets in Nasopharyngeal Cancer
Current Medicinal Chemistry Exosomes: The Messengers of Health and Disease
Current Neuropharmacology Simultaneous Interruption of Signal Transduction and Cell Cycle Regulatory Pathways: Implications for New Approaches to the Treatment of Childhood Leukemias
Current Drug Targets